Literature DB >> 30574858

An Unusual Case of Medullary Thyroid Carcinoma and A Revision of Current Literature.

Claudia Cipri1, Fabio Vescini1, Francesca Torresan2, Gianmaria Pennelli3, Maria Rosa Pelizzo2, Vincenzo Triggiani4, Edoardo Guastamacchia4, Franco Grimaldi1.   

Abstract

BACKGROUND: Medullary thyroid cancer (MTC) accounts for 5% of all thyroid cancers and occurs either sporadically or in a hereditary pattern. Routine calcitonin (CT) measurement is suggested for MTC screening in patients with nodular thyroid disease. PATIENT
FINDINGS: A 45 years-old woman incidentally discovered, with neck ultrasound, the presence of thyroid micronodules. Fine-needle aspiration (FNA) on thyroid prevailing nodule did not demonstrate cellular atypia. During follow-up, FNA was repeated on the previously analyzed nodule suspicious for Hürthle cell nodule suspicious for follicular neoplasm and on another hypoechoic right nodule which showed cellular atypia. CT was <2 pg/ml (normal values <18.2 pg/ml), anti-thyroid antibodies were positive and the patient showed a normal thyroid function. The patient also was diagnosed with primary hyperparathyroidism with an enlarged parathyroid gland behind the right thyroid lobe. Therefore, she underwent total thyroidectomy and a selective parathyroidectomy was performed. Histology showed an encapsulated microMTC (pT1aNxMx) associated with diffuse C-cell hyperplasia and lymphocytic thyroiditis. The neoplasm was positive for calcitonin and chromogranin A and negative for thyroglobulin. A right parathyroid adenoma was also diagnosed. One month after surgery basal and stimulated CT were <2 ng/ml. Genetic analysis did not reveal mutation of RET proto-oncogene. Twelve months after surgery, neck ultrasonography, chest and abdomen computed tomography did not demonstrated residual/recurrent disease with undetectable serum CT.
CONCLUSION: In the literature, few MTC cases with normal serum CT have been reported. Although MTC without elevated plasma CT is extremely rare, normal or low CT levels, do not entirely exclude this diagnosis. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Thyroid; calcitonin; medullary thyroid carcinoma; thyroid carcinoma; thyroid nodular disease; thyroidectomy.

Mesh:

Year:  2019        PMID: 30574858     DOI: 10.2174/1871530319666181220165350

Source DB:  PubMed          Journal:  Endocr Metab Immune Disord Drug Targets        ISSN: 1871-5303            Impact factor:   2.895


  4 in total

Review 1.  Is Encapsulated Medullary Thyroid Carcinoma Associated With a Better Prognosis? A Case Series and a Review of the Literature.

Authors:  Andrea Contarino; Alessia Dolci; Marco Maggioni; Francesca Maria Porta; Gianluca Lopez; Uberta Verga; Francesca Marta Elli; Elisabetta Francesca Iofrida; Gianmaria Cantoni; Giovanna Mantovani; Maura Arosio
Journal:  Front Endocrinol (Lausanne)       Date:  2022-04-27       Impact factor: 6.055

2.  Editorial: The Unusual Presentation of Thyroid Disorders.

Authors:  Giampaolo Papi; Alfredo Pontecorvi
Journal:  Front Endocrinol (Lausanne)       Date:  2019-08-20       Impact factor: 5.555

3.  Concomitant medullary thyroid carcinoma with paraganglioma-like pattern and papillary thyroid carcinoma.

Authors:  C Greco; G Brigante; E Taliani; S Corrado; M Simoni; B Madeo
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2019-11-28

4.  Metastatic medullary thyroid carcinoma presenting as ectopic Cushing's syndrome.

Authors:  Hannah E Forde; Niamh Mehigan-Farrelly; Katie Ryan; Tom Moran; Megan Greally; Austin G Duffy; Maria M Byrne
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2021-04-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.